A big story today is that the FDA, for the first time, has approved a so-called biosimilar drug.
The thrust of the news is mostly regulatory and economic:
biological drugs
As reported in today s Wall Street Journal, an FDA advisory panel has voted unanimously to recommend the approval of a new product from Novartis called Zarxio. Assuming that the FDA follows the panel s advice (they usually do), a bit of pharmaceutical history will be made the ability of companies to develop and market biologic drugs that are similar to those of other companies.